SeedFolio

HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. By addressing the root causes of these conditions, the company seeks to improve patient outcomes significantly. Their approach involves a unique targeted therapeutics platform that utilizes a two-site binding mechanism for HDAC6, which allows for the delivery of treatments that are both safe and effective. This strategy is designed to meet the substantial unmet medical needs associated with neuropathies and cardiometabolic diseases.

VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Vasa Therapeutics is a privately held biopharmaceutical company based in Encinitas, California, focused on developing therapies for vascular diseases. The company specializes in the discovery and development of treatments for conditions such as heart failure, peripheral artery disease, and sarcopenia. Vasa Therapeutics utilizes an in-house drug discovery testing funnel to identify promising small molecule and peptide therapeutics, aiming to provide healthcare professionals with effective options for managing these significant health issues.

Eversun, headquartered in San Diego, specializes in innovative, portable utility equipment designed to replace traditional fuel-based power and lighting systems. Their flagship product, the eTower, is a versatile, rapidly deployable unit that combines solar power, energy storage, communications, and lighting. Standing up to 23 feet tall in under a minute, the eTower integrates LEDs, cameras, and data networks, providing reliable power and connectivity for first responders, military units, disaster response teams, event organizers, and construction crews in off-grid locations. Eversun's commitment to sustainability sets it apart, as the eTower primarily uses renewable energy sources, reducing greenhouse gas emissions and dependency on non-renewable energy. The company offers customizable solutions, technical support, and digital lighting assessments to meet specific client needs, empowering remote site operations with efficient, portable, and sustainable power.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Trio Pharmaceuticals is a San Diego-based company focused on developing innovative cancer therapeutics. Founded in 2018, it specializes in dual-action drugs designed to combat immunogenic tumors. These therapeutics aim to halt tumor growth while selectively addressing immunosuppression within the tumor environment, distinct from conventional immune checkpoint pathways. By targeting specific antigens on cancer cells and immunosuppressor cells, Trio's drugs enhance tumor immunity, improve treatment efficacy, and reduce toxicity. The company's mission is to address significant unmet medical needs in cancer treatment, ultimately making therapies more accessible and affordable for patients.

Tiamat Sciences is a start-up focused on producing affordable, animal-free growth factors and biomolecules through innovative plant-based bioreactor technology. By leveraging its proprietary platform, the company manufactures a diverse array of high-value proteins, including antigens and growth factors, achieving significant cost reductions—up to 10 times lower than traditional methods, with potential for a 1000-fold decrease at scale while maintaining high growth margins. Tiamat's approach not only enhances production efficiency but also aligns with sustainability goals by providing ecological alternatives for the pharmaceutical industry, allowing for the reduction or replacement of animal-derived materials. With low facility investment requirements, Tiamat positions itself as an ideal partner for scaling production in emerging markets such as cellular agriculture and cell and gene therapy.

Duo Oncology is focused on developing innovative nanoparticle technology designed to effectively penetrate established tumors, particularly in challenging cases such as pancreatic and bile duct cancers. The company aims to transform treatment outcomes through a novel monotherapy that enhances patient care for those with hard-to-treat tumors and relapsed metastatic disease. By collaborating with leading university scientists and medical oncologists, Duo Oncology leverages a network of established research organizations to expedite the development of its products. The technology addresses significant needs in immunotherapy and precision medicine, ultimately striving to improve recovery times and patient outcomes.

Anvil Diagnostics is a biotechnology company focused on developing innovative diagnostic solutions. It specializes in creating a sensing technology that can rapidly and accurately detect a wide array of pathogens and genetic markers in blood samples, with the initial aim of identifying hundreds of such targets within a few hours. This technology, based on digital polymerase chain reaction (PCR), is designed to enable precision medicine, particularly for patients with sepsis, by providing timely and precise diagnostic information, thereby helping to resolve clinical ambiguity and improve patient outcomes.

RecoverX develops computational evidence and safe AI technologies to augment medical decision-making and advance new medical evidence.

GroGuru Inc. is a technology company based in La Jolla, California, that specializes in smart irrigation solutions for agriculture. Founded in 2014, GroGuru provides software as a service focused on irrigation monitoring and management. The company's platform utilizes an Internet of Things (IoT) sensor network to deliver precise measurements of soil moisture, salinity, and temperature. This data-driven system enables farmers to optimize water usage and improve crop yields by offering real-time insights and recommendations for irrigation scheduling and water management. GroGuru aims to promote sustainable farming practices while enhancing agricultural productivity and conserving water resources, ultimately helping farmers reduce input costs associated with water, energy, and fertilizer.

VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through its proprietary technology, Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This unique approach aims to harness pre-existing immune memory from pathogens or childhood vaccines to target and redirect the immune system toward tumors. By doing so, VerImmune seeks to address significant challenges in cancer treatment, particularly for patients with limited options or those who have developed resistance to conventional therapies. The company's strategy promises to offer low toxicity and sustained benefits across a diverse range of cancer types, potentially transforming the treatment landscape for those with difficult-to-treat malignancies.

EarthGrid is pioneering a novel approach to tunneling, trenching, and excavation through its patented plasma tunnel-boring technology. This innovative method utilizes high-power plasma torches to vaporize and break down materials such as rock and clay, enabling significantly faster operations and substantial cost savings compared to conventional techniques. The company's network of tunnels aims to enhance infrastructure and connectivity within communities by facilitating the movement of clean renewable energy, extending broadband access to underserved areas, and providing essential services like clean water and efficient transportation for e-commerce. EarthGrid's comprehensive infrastructure solutions are designed to create interconnected and sustainable environments, fostering improved access and quality of life for communities.

Veckta operates as an Energy Transition Market Platform that combines advanced energy system engineering tools with a comprehensive marketplace aimed at enhancing the development of distributed energy systems (DES) and microgrid projects. The platform enables businesses and communities to assess their current energy situation, tailor solutions that meet specific requirements regarding cost, reliability, and emissions, and efficiently connect with top-tier equipment, services, and capital providers. By facilitating informed decision-making through transparent pricing and global support, Veckta allows clients to design, finance, and construct their energy systems sustainably and profitably, ultimately contributing to a more habitable planet.

Ordaos Bio is a biomedical research company based in Manhattan, New York, established in 2019. It focuses on revolutionizing drug discovery and development through the integration of artificial intelligence and biology. The company operates a human-enabled, machine-driven platform that facilitates the design of novel immunotherapies for oncology and chronic inflammatory diseases. By providing an AI-driven drug discovery pipeline, Ordaos Bio empowers researchers to develop treatments that are more effective and safer than conventional methods, thereby addressing significant challenges in medical research and enhancing therapeutic outcomes.

AmplifiDX, founded in 2020 and based in Pleasanton, California, specializes in developing a molecular point-of-care device that offers rapid testing capabilities. The device is designed to deliver clear and actionable results for conditions such as COVID-19, achieving high sensitivity comparable to laboratory PCR tests. Notably, it provides results in as little as half an hour and is linked to mobile devices for enhanced user experience. By combining ease of use, low cost, and high performance, AmplifiDX aims to facilitate quick decision-making and help in the prompt isolation of infectious cases, thereby contributing to public health efforts.

PreView Medical is a company focused on developing an artificial intelligence-based optical diagnostic tool aimed at enhancing the detection and diagnosis of prostate cancer. Its innovative technology utilizes algorithms to generate a three-dimensional map of prostate tumors, which aids healthcare professionals in diagnosing prostate cancer early and optimizing treatment for cancer lesions. By improving the efficiency of cancer detection, PreView Medical seeks to contribute to better health outcomes for patients.

eGlint is a developer of a miniature biosensing device that utilizes a small volume of blood to detect multiple biomarkers. This innovative technology aims to enhance the efficiency of biomarker identification in the medical field. By offering a device capable of analyzing various biomarkers from a minimal blood sample, eGlint seeks to improve diagnostic processes and patient care within the healthcare industry.

Basilard BioTech operates a technology platform focused on advancing cell-based therapies, particularly in the field of Cell and Gene Therapies (CGT). This platform utilizes a nanomechanical gene delivery method, distinguishing itself by providing a mechanical approach to gene delivery rather than relying on biological processes. This innovative technique consistently achieves higher transfection rates, enhanced cell viability, and improved yields, thereby allowing clients to optimize their therapeutic outcomes. By harnessing the potential of cell functions, Basilard BioTech aims to address critical unmet clinical needs and contribute to solutions for diseases that impact millions of lives.

Amplo Biotechnology is focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at addressing severe diseases related to the neuromuscular junction, which can lead to paralysis, breathing difficulties, and swallowing challenges. The company targets conditions such as congenital myasthenic syndromes, leveraging its lead program, AAV-Dok7, developed by a research group at the University of Tokyo. The therapies are administered through intravascular injections, initiating molecular processes that enable effective treatment for patients suffering from these rare disorders. Amplo’s mission is to create potentially curative solutions for conditions that significantly impact patient health and quality of life.

Labviva, Inc. operates a digital marketplace tailored for the life sciences sector, connecting researchers with suppliers of reagents, chemicals, and laboratory equipment. Founded in 2015 and based in Somerville, Massachusetts, the platform offers a wide range of products, including antibodies, biological kits, buffers, chromatography supplies, and various laboratory devices. Labviva enhances the user experience by leveraging scientific context to streamline the procurement process, making it easier for suppliers to manage product content. Its Inventory Management System provides real-time inventory tracking and AI-driven purchase automation, thus improving operational efficiency and compliance. By offering insights into lab purchasing trends and supply chain health, Labviva enables clients to maintain contract pricing with preferred vendors and establish direct partnerships without the complexity of managing multiple catalogs.

Deep Blue Medical Advances, Inc. specializes in manufacturing innovative hernia mesh products aimed at improving surgical outcomes for hernia patients. Founded in 2015 and based in Durham, North Carolina, with an additional office in San Francisco, the company has developed the T-Line® hernia mesh, which features integral suture-like extensions designed to enhance fixation and reduce the risk of hernia recurrence. This novel design addresses a critical failure point in conventional mesh fixation, potentially leading to better patient outcomes and lower clinical costs in the $1.1 billion global hernia device market. Additionally, Deep Blue offers Anchor Clip fixation devices that facilitate faster and more reliable mesh implantation. The company's focus on improving the surgical experience and patient satisfaction positions it as a key player in the soft tissue surgery sector.

Inspirit is an education technology company specializing in virtual reality tools for science and STEM education. Founded in 2019 and based in Palo Alto, California, Inspirit provides educational institutions with a next-generation learning platform that features a comprehensive library of immersive labs and simulations. Their offerings include virtual labs and gamified experiences aimed at enhancing student engagement and understanding of complex scientific concepts. The platform also incorporates no-code creator tools, allowing educators to design custom simulations, experiments, and assessments tailored to their curriculum needs. With capabilities for classroom management and collaborative lab sessions, Inspirit's tools foster active participation and critical reasoning among learners, transforming the way science is taught globally.

Allotrope Medical Inc. is a Houston-based medical device company focused on enhancing surgical procedures by developing innovative devices for ureter identification. The company's flagship product, the StimSite, is an intuitive handheld device that aids surgeons in quickly and accurately locating ureters during pelvic surgeries. This device features a simple design with a single button, eliminating the need for complex pre- and post-operative procedures. Founded in 2016, Allotrope Medical aims to improve surgical outcomes by providing tools that streamline the identification and localization of ureters, thus facilitating safer and more efficient operations.

Maxwell Biomedical, Inc. is a medical device company focused on developing innovative solutions for the treatment of atrial fibrillation. Established in 2018 and located in Solana Beach, California, the company is pioneering a device designed to provide real-time, pain-free left atrial pacing to restore normal sinus rhythm in patients experiencing atrial fibrillation. This device continuously monitors for episodes of atrial fibrillation and employs a unique therapy called Spatial Resynchronization Therapy (SRT) to terminate these episodes without shock, thereby reducing the overall burden of the condition. Maxwell Biomedical's technology incorporates a fully integrated atrial fibrillation care system that facilitates remote patient management and telehealth capabilities, allowing healthcare providers to monitor and manage patients more effectively while potentially slowing or halting disease progression.

Ivy is a turn-key service powered by intelligent software providing equitable solar access to residents and predictable returns to owners.

PercAssist focuses on the development of percutaneous balloon catheters aimed at enhancing left ventricular function and facilitating myocardial recovery. The company's innovative approach features a battery-powered, non-blood contact extra-vascular device that is designed to be procedurally simple. This technology not only reduces recovery time but also minimizes long-term complications and hospitalizations, ultimately improving survival rates and quality of life for patients with severe heart failure. With a dedicated founding team and clinical advisory board, PercAssist is committed to addressing the significant unmet needs in the treatment of heart conditions.

Tiamat Sciences is a start-up focused on producing affordable, animal-free growth factors and biomolecules through innovative plant-based bioreactor technology. By leveraging its proprietary platform, the company manufactures a diverse array of high-value proteins, including antigens and growth factors, achieving significant cost reductions—up to 10 times lower than traditional methods, with potential for a 1000-fold decrease at scale while maintaining high growth margins. Tiamat's approach not only enhances production efficiency but also aligns with sustainability goals by providing ecological alternatives for the pharmaceutical industry, allowing for the reduction or replacement of animal-derived materials. With low facility investment requirements, Tiamat positions itself as an ideal partner for scaling production in emerging markets such as cellular agriculture and cell and gene therapy.

Strategikon Pharma, Inc. specializes in developing software that optimizes the outsourcing processes between sponsors and providers in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a unique platform designed for the comprehensive management of clinical business operations, particularly in planning, outsourcing, and budgeting clinical trials. By facilitating an integrated virtual environment, Clinical Maestro enables biopharmaceutical companies to efficiently manage complex relationships with numerous global service providers who often operate with varying processes and reporting structures. The software replaces traditional, labor-intensive methods—primarily reliant on Excel—leading to significant cost savings and enhanced operational efficiency. Case studies with major pharmaceutical firms highlight the platform's effectiveness, achieving over 80% savings compared to manual processes and over 95% accuracy in predicting clinical study budgets. Founded in 2016 and headquartered in San Rafael, California, Strategikon Pharma also offers consulting services to support new clinical business operations.

Abintus Bio, Inc. is a preclinical stage gene therapy company based in Encinitas, California, founded in 2020. The company specializes in in vivo immune cell reprogramming, aiming to develop innovative products that modulate immune cells directly within their native environment. By utilizing proprietary vectors and related technologies, Abintus Bio focuses on creating a portfolio of first-in-class product candidates designed to enhance patient outcomes by empowering the immune system to combat diseases more effectively.

Ready, Set, Food! is a California-based company founded in 2017 that specializes in manufacturing and selling infant food products designed to help reduce the risk of allergies to peanuts, eggs, and milk. The company offers a gentle, daily system that can decrease the likelihood of developing these common allergies by up to 80%. Its products are available for purchase online, making it accessible for parents seeking to introduce allergenic foods into their infants' diets safely.

Optimize Health is a digital healthcare provider specializing in remote patient monitoring (RPM) solutions. The company offers a user-friendly platform that incorporates both equipment and software designed to streamline the implementation of RPM programs. Its software aids healthcare providers in complying with Medicare billing requirements for RPM services while ensuring a positive experience for both patients and providers. The platform automatically tracks medication doses and sends reminders to users, leveraging Bluetooth technology to sync with smartphones and tablets. This approach empowers patients to manage their health effectively and enables physicians to achieve profitability from RPM services starting in the first month.

Everest Labs, founded in 2018 and based in Fremont, California, specializes in developing advanced robotics solutions for the waste management and scrap metal industries. The company's flagship product, Celer, employs artificial intelligence, machine learning, and computer vision to enhance the sorting and quality control processes at material recovery facilities. By integrating these technologies, Everest Labs aims to increase the quality of recyclables while minimizing reliance on human labor, thereby supporting revenue growth for waste management companies. The company is focused on fostering sustainability in the industry by encouraging the use of recycled materials in manufacturing and packaging. Ultimately, Everest Labs aspires to establish itself as a leading provider of AI and robotics solutions in complex environments like waste management.

Buzz Solutions, Inc. develops an artificial intelligence-based software platform aimed at enhancing the inspection of energy infrastructure, specifically power lines. Founded in 2017 and based in Palo Alto, California, the company offers an image-recognition solution that identifies defects and anomalies in utility infrastructure. The platform automates the process of storing and analyzing visual data collected through drones and helicopters, using AI algorithms to generate actionable insights, predictive analytics, and heat maps. This technology enables power utilities to significantly reduce the time and costs associated with data analysis by over 50%, facilitating condition-based maintenance. As a result, Buzz Solutions' offerings contribute to preventing wildfires, power outages, and other adverse effects related to climate change on critical grid infrastructure.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Tourmo is a technology company founded in 2014 and based in San Diego, California, that specializes in developing advanced software solutions for telematics data collection via smartphones. With a focus on automating manual processes, Tourmo utilizes artificial intelligence to simplify the complexities associated with transportation workforces, vehicles, and network fleets. The company's platform delivers contextualized business intelligence and real-time decision-making capabilities, enabling organizations to enhance their operational efficiency and support their critical networks of personnel, vehicles, customers, and partners. Tourmo holds two U.S. patents related to telematics and drive-data collection, positioning itself as a leader in providing innovative solutions for mobile phone manufacturers, carriers, and app development companies in the U.S. and Europe.

AccessParks is a provider of outdoor internet services that delivers high-speed broadband access to parks and campgrounds. The company offers fully managed, fiber optic-fed Wi-Fi capable of supporting over 4,000 devices streaming video simultaneously. AccessParks oversees the entire network infrastructure, from the fiber connections to the devices used by guests, ensuring reliable service. Their commitment to quality is reinforced by 24/7 support and a dedicated network operations center that continuously monitors and optimizes network performance. By focusing on uninterrupted internet access, AccessParks enables park and campground authorities to enhance the guest experience with reliable connectivity.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

Resynergi addresses the global issue of waste plastics by developing innovative technology that converts non-recyclable plastics into environmentally friendly fuels and chemical products. The company manufactures modular, low-emission plastic-to-hydrocarbon oil conversion systems that utilize a microwave-based process to transform unrecycled waste plastic into biodiesel. These systems are designed to be easy to deploy, scalable, and highly cost- and energy-efficient, allowing clients to obtain low carbon-intensity fuels from a wide variety of feedstocks. By focusing on recycling chemically valuable plastics, Resynergi aims to provide sustainable solutions for waste management and energy production.

Regenosine is a healthcare center focused on developing regenerative therapies aimed at tissue regeneration, particularly for cartilage and joint preservation. The company utilizes a purinergic system that helps regulate and maintain tissue homeostasis while restoring adenosine levels. This innovative approach allows users to leverage the healing potential of adenosine to promote tissue recovery and regeneration. Regenosine also offers an online inquiry form on its website, facilitating communication and information requests regarding its products and services.